Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

447results about How to "Reduced Tolerance Requirements" patented technology

Polymer controlled induced viscosity fiber system and uses thereof

InactiveUS7067498B2Blunt glycemic responsePrevent dissolutionBiocideSugar food ingredientsPhysical stabilityChemistry
The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.
Owner:ABBOTT LAB INC

Medication delivery system with improved dose accuracy

The invention relates to: A medication delivery device (1) for delivering a specific dose comprising a medication cartridge (11) having an outlet (111) and a piston (112), and means (12) for holding said cartridge, and a piston rod (13) being operable to engage and displace said piston, and electrically driven actuating means (15), and driving means (161, 162) for transferring movement from said actuating means to said piston rod, and memory means (17) for storing data, and processing means (18) for evaluating said data and for controlling said actuating means. The object of the present invention is to provide a medication delivery system that combines a relatively high dose accuracy with the use of relatively low quality mechanical components and which enables compensation for built-in non-linearities. The problem is solved in that a first set of data (19) describing the actual movement (130) of said piston rod (13) relative to said medication cartridge (11) as a function of the movement (150) of said actuating means (15) is stored in said memory means (17), and the movement (130) of the piston rod (13) governing the delivered dose is controlled by the processing means (18) on the basis of said first set of data (19). This has the advantage of allowing compensation for mechanical inaccuracies and built-in non-linearities linearities. The invention may e.g. be used in injection or infusion devices for a person's self-treatment of a disease such as diabetes.
Owner:NOVO NORDISK AS

Developer amount detector, and developer container, development device, and image forming apparatus incorporating same

ActiveUS20120189327A1High precisionAdverse effects caused by the fluctuations to the light transmission can be reducedElectrographic process apparatusEngineeringLight guide
A development device includes a development housing, a first developer conveyance member, a developer bearer, and a developer amount detector to detect an amount of developer in the development housing. The developer amount detector includes a light-emitting element, a right-receiving element, a first light guide including a first end from which light enters and a second end disposed inside the development housing, and a second light guide including a first end positioned inside the development housing across a predetermined distance from the second end of the first light guide and a second end from which the light exits. The second end of the first light guide and the first end of the second light guide are arranged in an axial direction of the first developer conveyance member with a light transmission path therebetween partly inside a locus of rotation of the first developer conveyance member.
Owner:RICOH KK

Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor

InactiveUS20070191412A1Reduce plasma concentrationEffective pain managementBiocideNervous disorderDrugCyclooxygenase
Disclosed is a pharmaceutical composition, comprising two analgesic compounds and / or pharmaceutically acceptable salts thereof consisting of celecoxib and / or at least one pharmaceutically acceptable salt thereof and oxycodone and / or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising orally administering to the patient an oral dosage form comprising two analgesic compounds consisting of celecoxib and / or at least one pharmaceutically acceptable salt thereof and oxycodone and / or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient.
Owner:PURDUE PHARMA LP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products